Abstract
The Intergroup 0116 (INT 0116) has established chemoradiation as the standard treatment for resected gastric cancer in Western countries. More recently, there has been a debate on the role of radiation in the treatment of diffuse-type adenocarcinoma of the stomach. Here we discuss the evidence and controversies that surround this issue. At this point of current knowledge, we recommend adjuvant chemoradiation for the treatment of resected diffuse-type adenocarcinoma of the stomach.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- 5-FU + LV:
-
5-fluorouracil plus leucovorin
- CMT:
-
Chemotherapy
- CRT:
-
Chemoradiation
- CT:
-
Computerized tomography
- DFS:
-
Disease-free survival
- Gy:
-
Gray
- HR:
-
Hazard ratio
- OR:
-
Odds ratio
- OS:
-
Overall survival
- RFS:
-
Relapse-free survival
- RT:
-
Radiation therapy
- XP:
-
Capecitabine and cisplatin
- XRT:
-
Capecitabine with radiation therapy
References
Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys. 1982;8(1):1–11.
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.
Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol. 2012;30(19):2327–33.
Dent DM, Madden MV, Price SK. Randomized comparison of R1 and R2 gastrectomy for gastric carcinoma. Br J Surg. 1988;75(2):110–2.
Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group Br J Cancer. 1999;79(9–10):1522–30.
Viste A, Svanes K, Janssen CW Jr, Maartmann-Moe H, Søreide O. Prognostic importance of radical lymphadenectomy in curative resections for gastric cancer. Eur J Surg. 1994;160(9):497–502.
Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449–61.
Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–49.
Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73.
Park SH, Sohn TS, Lee J, do DH L, Hong ME, Kim KM, et al. Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses. J Clin Oncol. 2015;33(28):3130–6.
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.
Shapiro J, van Lanschot JJ, Hulshof MC, van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090–8.
Stessin AM, Sison C, Schwartz A, Ng J, Chao CK, Li B. Does adjuvant radiotherapy benefit with diffuse-type gastric cancer? Results from the surveillance, epidemiology, and end results database. Cancer. 2014;120(22):3562–8.
Dai Q, Jian L, Lin RJ, Wei KK, Gan LL, Deng CH, et al. Adjuvant chemoradiotherapy versus chemotherapy for gastric cancer: a meta-analysis of randomized controlled trials. J Surg Oncol. 2015;111(3):277–84.
Marrelli D, Roviello F, de Manzoni G, Morgagni P, Di Leo A, Saragoni L, et al. Italian research Group for Gastric Cancer. Different patterns of recurrence in gastric cancer depending on Lauren’s histological type: longitudinal study. World J Surg. 2002;26(9):1160–5.
Vasconcelos K, Chen ATC, Hong CBC, Nakazato D, Stelko G, Hoff PMG, et al. Liver irradiation increases relapse-free survival in adjuvant gastric cancer treatment. Int J Radiat Oncol Biol Phys. 2013;87(2 Suppl 2257):S301.
Park SH, Lee SJ, Kim ST, Lee J, Park JO, Park YS, et al. Multicenter phase III trial of adjuvant chemoradiotherapy in stomach tumors 2 (ARTIST 2). J Clin Oncol. 2015;33(Suppl 3):TPS228.
Verheij M, Jansen EPM, Cats A, van Grieken NCT, Aaronson NK, Boot H, et al. A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study. J Clin Oncol. 2016;34(Suppl 15):4000.
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=83497.
Tepper JE, Gunderson LL. Radiation treatment parameters in the adjuvant postoperative therapy of gastric cancer. Semin Radiat Oncol. 2002;12(2):187–95.
Ashman JB, Callister MD, Jaroszewski DE, Ross HJ, Ezzell GA, Gunderson LL. Trimodality therapy for distal esophageal/esophagogastric junction adenocarcinoma using three-dimensional conformal and intensity modulated radiotherapy. Int J Radiat Oncol Biol Phys. 2010;78(3 Suppl 2222):S303.
Chopra S, Agarwal A, Engineer R, Dora T, Thomas B, Sonawone S, et al. Intensity modulated radiation therapy (IMRT) is not superior to three-dimensional conformal radiation (3DCRT) for adjuvant gastric radiation: a matched pair analysis. J Cancer Res Ther. 2015;11(3):623–9.
Trip AK, Nijkamp J, van Tinteren H, Cats A, Boot H, Jansen EP, et al. IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer. Radiother Oncol. 2014;112(2):289–94.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Chen, A.T.C., Hong, C.B.C. (2018). The Role of Radiation Therapy. In: de Castria, T., Guindalini, R. (eds) Diffuse Gastric Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-95234-5_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-95234-5_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-95233-8
Online ISBN: 978-3-319-95234-5
eBook Packages: MedicineMedicine (R0)